Crossmark

Thalidomide maintenance therapy in Japanese myeloma patients: a multicenter, phase II clinical trial (COMET study)

Crossref DOI link: https://doi.org/10.1007/s12185-019-02607-z

Published Online: 2019-01-31

Published Print: 2019-04

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Murakami, Hirokazu

Kasamatsu, Tetsuhiro

Murakami, Jun

Kiguchi, Toru

Kanematsu, Takeshi

Ogawa, Daisuke

Takamatsu, Hiroyuki

Handa, Hiroshi

Ozaki, Shuji

Miki, Hirokazu

Takahashi, Takeshi

Takeo, Takaaki

Yamauchi, Tatsuya

Morishita, Takanobu

Kosugi, Hiroshi

Shimizu, Kazuyuki
License Information

Text and Data Mining valid from 2019-01-31
More Information

Article History

Received: 16 October 2018

Revised: 20 January 2019

Accepted: 23 January 2019

First Online: 31 January 2019

Change Date: 22 May 2019

Change Type: Correction

Change Details: The authors would like to correct the errors in the publication of the original article. The correction details are given below.

Compliance with ethical standards

:

: Dr. Murakami H received a research grant from Fujimoto Pharmaceutical Co. Ltd. and Celgen Co. Ltd, and served on scientific advisory boards and speakers’ bureaus for Celgen Co. Ltd., Sanofi K.K., and Ono Pharmaceutical CO, Ltd. Dr. Kiguchi T received a research grant from Celgen Co. Ltd., Sanofi K.K., and Janssen Pharmaceutical K.K. Other authors have no conflict of interest.